Medtronic plc Consolidated Statement of Income \begin{tabular}{|l|r|} \hline \multicolumn{1}{|c|}{ (\$ millions) } & Apr. 29, 2016 \\ \hline Net sales & $29,277 \\ \hline Costs and expenses & \\ \hline Cost of products sold & 9,142 \\ \hline Research and development expenses & 2,224 \\ \hline Selling, general, and administrative expense & 9,469 \\ \hline Special charges (gains), net & 70 \\ \hline Restructuring charge, net & 290 \\ \hline Certain litigation charges, net & 26 \\ \hline Acquisition-related items & 283 \\ \hline Amortization of intangiable assets & 1,931 \\ \hline Other expense, net & 107 \\ \hline Operating profit & 5,735 \\ \hline Interest expense, net & 955 \\ \hline Income from operations before income taxes & 4,780 \\ \hline Provision for income taxes & 908 \\ \hline Net income & $3,872 \\ \hline \end{tabular} a. Use the financial statements along with the additional information below to forecast retained earnings for FY2017. Forecasted retained earnings $ million b. Suppose the MD\&A section of the Form 10- K and additional guidance from the company reveals the following additional information. At FY2016 year-end (April 29, 2016), the company had approximately 1,400 million shares issued and outstanding. Use this information to refine your forecast of retained earnings for FY2017. Forecasted retained earnings $ million